Dr. Mounzer E. Agha, MD

Dr. Agha practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Dr. Agha's NPI, 1669442638, was assigned on January 24, 2006. Dr. Agha graduated from University of Aleppo Faculty of Medicine in 1983. Dr. Agha holds Pennsylvania license MD040710L.

Dr. Agha's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Dr. Agha's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Dr. Agha is also affiliated with UPMC Presbyterian. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Dr. Agha to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Agha practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Agha's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Agha is board certified in hematology by the American Board of Internal Medicine. Dr. Agha is licensed in Pennsylvania.

Dmand AI lists anemia, chronic anemia, chronic leukemia, deep vein thrombosis (DVT), immune deficiency disease, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Agha treats.

CMS data shows 971 Medicare services from Dr. Agha across 11 procedure codes in 2024, for 282 Medicare patients. Medicare paid $76,679 for them.

CMS counts 282 Medicare patients who saw Dr. Agha in 2024. The largest group is 65 to 74, with 152 patients. 74% of them have high cholesterol, and 71% have high blood pressure. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Agha's median patient age at 72, with 42% women.

In 2024, Dr. Agha wrote 1,728 Medicare Part D claims for 195 patients. 58% of them were for generic drugs. CMS names the drug for 1,486 of them, across 36 drugs with 11 or more claims each, at $8,454,209 in total drug cost. In 2023, CMS named 1,456 claims across 41 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Dr. Agha for performance year 2024, reported as part of a group. Dr. Agha accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Agha as offering telehealth.

Dmand AI links 67 papers to Dr. Agha, published from 2010 to 2024. 2021 was the busiest year, with 8. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Hematopoietic Stem Cell Transplantation. Dr. Agha has published most often in Leuk Lymphoma. Dr. Agha's most frequent co-authors are Anastasios Raptis, Kathleen Anne Dorritie, MD and Annie Pearl Im, MD.

Dmand AI links Dr. Agha to 7 clinical trials, 2 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Myeloproliferative Disorders. Medical College of Wisconsin sponsors the most, 2.

CMS Open Payments shows 25 general payments to Dr. Agha from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 46% of the total. Verastem, Inc. paid the most, $6,062.

Dr. Agha graduated from University of Aleppo Faculty of Medicine in 1983. Dr. Agha is a member of ASCO.

Dr. Agha is in network with 17 carriers, including Excellus BlueCross BlueShield, Highmark and United Healthcare. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.